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KEY POINTS
 Syndromic and point-of-care molecular diagnostic testing methods have revolutionized infectious disease testing by
permitting the simultaneous detection of multiple pathogens and drug resistance mechanisms directly from clinical
specimens and positive blood cultures.
 Syndromic testing panels currently include those designed for the detection of pathogens responsible for bloodstream,
central nervous system, gastrointestinal tract, and respiratory tract infections as well as some biothreat agents.
 Point-of-care molecular diagnostic systems afford providers the ability to generate laboratory-quality results without the
need for confirmatory testing of negative specimens.
 Implementation of syndromic and point-of-care molecular infectious disease testing methods has curbed the
unnecessary use of antibiotics, strengthening antimicrobial stewardship practices.
 Development of methods for the detection of infectious diseases beyond those that are detectable by current
technologies is an area of investigation.INTRODUCTION
For decades, the clinical laboratory diagnosis of many
infectious diseases relied solely on time-consuming
and often labor-intensive manual cultivation-based,
microscopic, and immunoserologic methods that
required experienced technical personnel to perform
and interpret. The introduction of semiautomated and
fully automated microbial phenotyping systems in the
later part of the 20th century vastly improved the pro-
cesses of bacterial and yeast isolate workup by
decreasing identification and antimicrobial susceptibil-
ity testing turnaround times (TATs); however, the detec-
tion of many viruses and parasites still required
traditional techniques. Subsequent improvements to*Corresponding author, E-mail address: rrelich@iupui.edu
https://doi.org/10.1016/j.yamp.2018.07.007
2589-4080/18/ © 2018 Elsevier Inc. All rights reserved.automated platforms, including the refinement of the
automated expert systems used by these devices to
generate and interpret data, led to further decreases in
TATs and a concomitant increase in culture throughput.
In the 1990s, the era of molecular diagnostics was
ushered in with the introduction of nucleic acid analysis
methods, including the hybridization protection assay
(eg, AccuProbe, Salem, MA) for the identification of iso-
lates and polymerase chain reaction (PCR) for the detec-
tion of pathogens directly from patient specimens [1–7].
Later, the implementation of real-time nucleic acid
amplification chemistries permitted both faster pathogen
detection and the enablement of nucleic acid quantita-
tion [8]. These methods quickly migrated from researchwww.advancesinmolecularpathology.com
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developed tests or so-called home brew tests. This revolu-
tion enabled laboratorians to more precisely identify the
causes of infectious diseases by detecting pathogen-
specific nucleotide sequences in cultured isolates and
clinical specimens. Many of these methods proved to
be far superior in terms of accuracy and result TAT
compared with cultivation-dependent approaches, espe-
cially for the identification of viruses. Over time, these
methods also underwent refinements that included the
adaptation of several assays to automated platforms,
allowing users tominimize themanual handling of spec-
imens and reaction components.
One recent advancement in pathogen detection is
the syndromic approach in which groups of pathogens
are tested for simultaneously in a single reaction vessel.
These assays incorporate components of older methods,
including real-time PCR; however, rather than ordering
separate tests for various pathogens, the syndromic tests
allow simultaneous detection of a variety of agents that
are associated with a specific disease syndrome [9].
The newest systems are those that allow users to
perform laboratory-quality molecular testing at the
point of patient care, a major advancement that has
moved molecular pathology to the forefront of modern
diagnostics. Many Clinical Laboratory Improvement
Amendments (CLIA)-waived point-of-care (POC) sys-
tems are now available and permit rapid result report-
ing, enabling prescription of targeted treatment at the
time of clinic visit. The current assays on these platforms
largely target infections diagnosed in the ambulatory
setting such as influenza and streptococcal pharyngitis.SIGNIFICANCE
Syndromic and POC molecular testing methods have
revolutionized the diagnosis of infectious diseases by
increasing the accuracy of microbial detection, substan-
tially decreasing the time needed to generate clinically
useful laboratory test results, and enabling the perfor-
mance of laboratory-quality testing at or near the point
of care by nonlaboratorians [9]. In return, patients are
able to receive appropriate treatment sooner, avoiding
prolonged exposure to unnecessary antimicrobial
drugs, thereby avoiding the selection of drug-resistant
pathogens and strengthening antimicrobial stewardship
practices [9–11]. In addition, many of these methods
permit the rapid detection of pathogens that pose sig-
nificant infection control and public health hazards,
including high-consequence and travel-related patho-
gens (eg, Bacillus anthracis, Ebola virus, and Plasmodium
spp.) that can be associated with either naturallyacquired infections or infections resulting from the
deliberate release of these agents. As a consequence of
the rapid TATs of these tests, containment and epidemi-
ologic interventions can be instituted very soon after
specimen acquisition.
In addition to the syndromic and POC molecular
testing solutions available for aiding in the identifica-
tion of pathogens, many test panels are also capable
of detecting antimicrobial resistance mechanisms
[9,12,13], the rapid detection of which affords clini-
cians and infection control practitioners the ability to
quickly implement appropriate therapies and infection
control precautions. The diagnostic power of these tech-
nologies coupled with their user friendliness have made
them highly attractive alternatives to traditional
methods that rely on the procurement of isolates. As a
consequence, methods such as viral culture and direct
immunofluorescence have largely disappeared from
modern clinical microbiology laboratories. With these
methods removed, many laboratories have streamlined
the workup of clinical specimens by using one syn-
dromic testing platform for the analysis of a variety of
specimen types for a large array of pathogens.PRESENT RELEVANCE AND FUTURE
AVENUES TO CONSIDER/INVESTIGATE
Currently, numerous diagnostic product manufacturers
market infectious disease syndromic panels and POCmo-
lecular tests that are available in a variety of formats,
including customizable panels, single-analyte tests, and
CLIA-waived and moderate complexity systems. These
tests were designed to provide all of the advantages that
traditional molecular diagnostic tests offer plus the bene-
fits of rapid result delivery, portability, and ease of use.
The ability of many of these test platforms to be success-
fully used by nonlaboratorians have made them
amenable to deployment in patient care facilities such as
clinics and hospital emergency departments, which are
traditionally not staffed by medical laboratory scientists.
Several syndromic and POC testing systems that pro-
vide qualitative results are described herein. Please note
that not all available systems are mentioned, but those
with a visible market presence in the United States are
discussed.
Currently Available Syndromic Panel
Platforms
BD MAX system
The BDMAX System (BD Diagnostics, Quebec, Canada;
Fig. 1) is an automated real-time PCR platform using
TaqMan hydrolysis probes for detection. In addition
FIG. 1 The BD MAX System, which is comprised of (A) a rack for holding specimens (blue-capped tubes in
front) and reagent strip, (B) the PCR cartridge, and (C) the BD MAX instrument. (Courtesy of BD, Sparks, MD;
with permission.)
Syndromic and Point-of-Care Molecular Testing 99to syndromic panels (see Table 1 and Table 3), the sys-
tem is designed to run singleplex and user-defined as-
says. To perform testing, specimens in sample buffer,
reagents, extraction wells, pipette tips, and a real-time
PCR microfluidic cartridge is placed on board the BD
MAX instrument, which automates all sample handling
and real-time PCR steps (see Fig. 1). Up to 24 assays can
be run simultaneously and results are available within
3 hours. Panel performance characteristics are reviewed
in refs. [14–17].ePlex, ePlex NP, and eSensor XT-8 systems
The ePlex, ePlex NP, and XT-8 systems (GenMark Diag-
nostics, Inc., Carlsbad, CA; Fig. 2) use patented eSensor
technology to detect a variety of pathogens directly
from patient specimens (ePlex and ePlex NP systems)
and amplified nucleic acid mixtures (eSensor XT-8
system).
For the ePlex system, the specimen in a buffer so-
lution is added to the ePlex panel in which all liquid
handling steps are performed by digital microfluidics
technology (electrowetting) [14]. Electrochemical
detection of ferrocene-labeled PCR amplicons occurs
via capture probes that have been immobilized on
gold-plated electrodes [15]. Results are generally
available within 90 minutes, and anywhere from 3
to 24 assays can be ran simultaneously, dependingon the instrument configuration (the ePlex NP per-
forms a maximum of 3 tests at once). In contrast,
the eSensor XT-8 system, the predecessor of the ePlex
system, is designed to simultaneously interrogate up
to 24 samples that have undergone offline nucleic
acid amplification; results are available within 30 mi-
nutes [15]. Analytes detectable by the current panels
are listed in Table 2 and performance characteristics
and impacts of these systems are discussed in refs.
[18–21].FilmArray system
The FilmArray system (BioFire Diagnostics and Bio-
Fire Defense, LLC, Salt Lake City, UT; Fig. 3) family
of syndromic panels includes several assays that are
cleared by the US Food and Drug Administration
(FDA) and several research use only assays (Box 1,
see Table 2; Tables 3 and 4). Of note, BioFire Defense
offers research-use-only reagents panels that are
designed for detection of high-consequence and
emerging pathogens whose detection could signal
possible bioterrorism events, and for pathogens asso-
ciated with travel to areas of the world where certain
infectious diseases that are rare in the United States
are endemic (Table 5).
The FilmArray System incorporates lyophilized re-
agents and assay reaction vessels on a small plastic
TABLE 1
Overview of Analytes Detected by the BD MAX Women’s Health Panels, CT/GC/TV, and Vaginal Panel
Analyte
FDA
Cleared?
Atopobium
vaginae
Bacterial
Vaginosis-
Associated
Bacteria-2
Candida
spp.a
Chlamydia
trachomatis
Gardnerella
vaginalis
Lactobacillus
spp.b Megasphaera-1
Neisseria
gonorrhoeae
Trichomonas
vaginalis
BD MAX
CT/GC/TV
1    1    1 1
BD MAX
Vaginal
Panelc
1 1 1 1  1 1 1  1
Abbreviations: CT/GC/VT, Chlamydia trachomatis/gonococcus (Neisseria gonorrhoeae)/Trichomonas vaginalis; FDA, US Food and Drug Administration.
Symbols: 1, yes or present on panel; -, no or absent from panel.
a The BD MAX vaginal panel detects Candida albicans, C dubliniensis, C glabrata, C krusei, C parapsilosis, and C tropicalis but reports them as “Candida group” for all
except C glabrata and C krusei, which it reports individually.
b The BD MAX Vaginal Panel detects Lactobacillus crispatus and L jensenii, which are grouped as Lactobacillus species.
c Detection of 1 or more bacterial analytes are reported as positive or negative for bacterial vaginosis.
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FIG. 2 The ePlex (A), ePlex NP (B), and eSensor XT-8 (C) systems available from GenMark Diagnostics. Also
shown are examples of ePlex (D) and XT-8 (E) panels. The nucleic acid hybridization complex described in the
text is shown in (F). (Courtesy of GenMark Diagnostics, Carlsbad, CA; with permission.)
Syndromic and Point-of-Care Molecular Testing 101film pouch topped by a solid plastic reagent housing
(Fig. 3A). After reagent rehydration, the sample in
buffer is added to a pouch that is then loaded into a Fil-
mArray instrument for automated nucleic acid extrac-
tion, real-time PCR, detection, and high-resolution
melt steps. The hands-on time of this system is minimal
(approximately 2 minutes) and results are generally
available in approximately 60 minutes [18]. Like the
ePlex system, the FilmArray 2.0 and Torch instruments
are scalable. With the exception of the FilmArray
BCID Panel, which is meant for testing blood culture
broths, all other panels are amenable to the direct
testing of clinical specimens. The FilmArray BioThreat
Panel, BioThreat-E Test, and Global Fever Panel are
designed to test a variety of sample types, which are
listed in the notes in Box 1. Numerous studies
describing the performance characteristics and benefits
of the FilmArray System have been published; examples
can be found in refs. [13,22–31].
Unyvero system
The Unyvero Lower Respiratory Tract Panel (Curetis
USA Inc., San Diego, CA; Fig. 4), known as the Pneu-
monia Panel in Europe, is the first multiplex lower res-
piratory tract infection testing system to receive FDA
clearance as of April 2018. This system uses PCR to
detect an array of bacterial pathogens and antimicro-
bial resistance genes (Table 6) directly from tracheal as-
pirates in 4 to 5 hours. The Unyvero system iscomposed of 3 hardware components: a sample lysis
device (Unyvero L4 Lysator), a panel analyzer (Uny-
vero A50 Analyzer), and a touchscreen computer inter-
face and barcode scanner (Unyvero C8 Cockpit).
Performance characteristics are described in refs.
[32,33].
VERIGENE system
The VERIGENE system (Luminex Corporation. Austin,
TX; Fig. 5) consists of VERIGENE Processor SP mod-
ules and the VERIGENE Reader, designed around a
family of FDA-cleared syndromic panels. Multiple Pro-
cessor SP units can be combined with a single Reader
to accommodate the simultaneous testing of multiple
samples. The extraction tray containing the sample,
test cartridge (see Tables 2 and 3 for cartridges and
analytes), tip holder assembly, and utility tray are
loaded into the Processor SP for automated nucleic
acid extraction, purification, target amplification (if
required by the specific assay), and hybridization of
the target molecules to a glass detection array in the
test cartridge. NanoGrid Technology is used to cap-
ture, detect, and identify target molecules. After the
processing step, the test cartridge array is placed into
the VERIGENE Reader to obtain results, which may
be selectively reported. Total hands-on, automated
processing, and test interpretation time is less than
3 hours. Performance characteristics are described in
refs. [34,35].
TABLE 2
Syndromic Panels that Are Currently Available in the United States for the Detection of Upper Respiratory Tract Pathogens
Analyte
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ePlex RP 1 1    / 1 1 1 1 1 1  1  1 1 1 1 1 1 1  1 1 1
eSensor RVP 1 1 1         1c  1  1 1 1  1 1 1   1 1
FilmArray RP Panel 1 1    1/ 1 1 1 1 1 1  1  1 1 1 1 1 1 1  1 1 
FilmArray RP2 Panel 1 1    1/1 1 1 1 1 1 1  1  1 1 1 1 1 1 1  1 1 
FilmArray RP EZa 1 1    1/ 1 1 1 1 1 1/1  1  1 1 1 1 1 1 1  1 1 
NxTAG RPPb 1 1    / 1 1 1 1 1 1 1 1  1 1 1 1 1 1 1   1 1
VERIGENE RP Flexb 1 1  1 1 1/1      1c  1  1 1 1 1 1 1 1   1 1
Abbreviations: FDA, US Food and Drug Administration; RPP, respiratory pathogen panel.
Symbols: 1, yes or present on panel; -, no or absent from panel.
a The FilmArray RP EZ assay tests for human coronaviruses HKU1, NL63, 229E, and OC43 and human parainfluenza viruses 1, 2, 3, and 4, but it reports those analytes as
coronavirus and parainfluenza virus, respectively.
b The NxTAG and VERIGENE RP flex assays allow users to selectively report targets.
c Rhinovirus alone is reported by the eSensor RVP, VERIGENE RP flex, US versions of the NxTAG RVP assays.
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BOX 1
Central Nervous System Pathogens Detected by
the FilmArray ME Panel
Bacteria
Escherichia coli K1
Haemophilus influenzae
Listeria monocytogenes
Neisseria meningitidis
Streptococcus agalactiae
Streptococcus pneumoniae
Fungia
Cryptococcus neoformans/C gattii
Viruses
Cytomegalovirus
Enterovirus
Herpes simplex virus 1
Herpes simplex virus 2
Human herpes virus 6
Human parechovirus
Varicella-zoster virus
a The FilmArray ME Panel detects C neoformans and C gattii but re-
ports them together as C neoformans/C gattii.
Syndromic and Point-of-Care Molecular Testing 103xTAG technology
In addition to the VERIGENE system, Luminex offers
FDA-cleared bead hybridization-based (xTAG) assays
that require offline nucleic acid extraction followed by
multiplex PCR and bead hybridization in 96-well plates.
Analysis of beads is carried out by the MAGPIX instru-
ment (Fig. 6). The MAGPIX instrument interrogates
beads in each well of the reaction plate to detect fluores-
cent reporters that are linked to bead-hybridized target
molecules. The total time required to perform a run is
approximately 5 hours, so batch testing of samples is
required. The NxTAG next-generation Respiratory Path-
ogen Panel allows users to selectively report analytes
(see Table 2) whereas the xTAG Gastrointestinal Path-
ogen Panel (see Table 3) does not. See refs. [36–38] for
performance characteristics.
Brief Description of Currently Available
Syndromic Panels
Blood culture
Accurate diagnosis and early, appropriate treatment of
sepsis is a life-saving event. Syndromic panels are
designed to use the exponential growth of organisms
in broth-based blood culture systems to detect themost common causes of bacteremia and key resistance
mechanisms that would alter therapeutic management
(eg, methicillin resistance). The performance of these
systems has been thoroughly reviewed elsewhere [39].
Of note, FilmArray and VERIGENE correctly detect
more than 95% of identifiable organisms in monomi-
crobial cultures when compared with conventional
methods. The Achilles heel of blood culture syndromic
panels is miscalls, which are associated with polymicro-
bial cultures and, more specifically, those errors associ-
ated with antimicrobial resistance.
Central nervous system
Infectious meningitis and encephalitis are oftenmedical
emergencies requiring prompt and accurate diagnosis
and intervention for favorable outcomes. Culture is
suboptimal for detecting many etiologies; however,
most laboratories lack the infrastructure to perform
laboratory-developed molecular tests and, therefore,
rely on reference laboratories for viral detection in the
cerebrospinal fluid or when the patient is on antimicro-
bials. Widespread early adoption has been plagued by
concerns around performance in a setting where misdi-
agnosis could be catastrophic. As with the respiratory
panel, the correlation of results without a sensitive
and specific gold standard is challenging. A multicenter
evaluation established a high percent agreement
(>99%) with comparator testing; however, the percent
agreement for positive results was only 84.4% [40].
Furthermore, reports of false-negative (eg, potential
suboptimal detection of herpesviruses and Cryptococcus)
and false-positive results (eg, Streptococcus pneumoniae
and herpes simplex virus-1) have resulted in delayed
or missed meningitis diagnoses [41].
Gastrointestinal
Acute gastroenteritis presents a clinical and public
health dilemma because the symptoms of infectious
and noninfectious causes of diarrhea overlap. Tradi-
tional diagnostics (eg, culture, microscopy, antigen
detection) are time consuming and may require multi-
ple specimens for optimal sensitivity. Studies have
reproducibly shown that 2 to 3 times more pathogens
are detected when a molecular assay is used, compared
with traditional methods [39]. This is due in part to an
enhanced range of the targets, an increase in sensitivity
of the assays over traditional methods, and the recogni-
tion of co-infections that were previously unrecognized.
Sensitivity and specificity of these assays, overall, is
high, with few exceptions. Notably, detection of rota-
virus, Campylobacter spp., and Salmonella spp. may be
problematic with VERIGENE; one publication noted
TABLE 3
Syndromic Panels that Are Currently Available in the United States for the Detection of Gastrointestinal Tract Pathogens
Analyte
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BD MAX Enteric
Bacterial Panel
1   1     1   1  1     1  1    
BD MAX Extended Enteric
Bacterial Panel
1   1     1    1 1   1  1  1 1 1 1 1
BD MAX Enteric
Parasite Panel
1     1  1       1          
FilmArray GI Panela 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
VERIGENE EP Testb 1   1          1  1  1 1  1 1 1  1
xTAG GPPc 1 1  1 1 1  1 1    1 1 1 1  1 1  1 1   
Abbreviations: EIEC, Shigella/enteroinvasive E coli; EAEC, Enteroaggregative E coli; EPEC, Enteropathogenic E coli; ETEC, Enterotoxigenic E coli; STEC, Shiga Toxin-producing E coli;
FDA, US Food and Drug Administration; GI, gastrointestinal; GPP, gastrointestinal pathogen panel.
Symbols: 1, yes or present on panel; -, no or absent from panel.
a The FilmArray GI panel detects Campylobacter jejuni, C coli, and C upsaliensis and reports them as “Campylobacter (jejuni, coli and upsaliensis).” Shigella spp. are re-
ported along with E coli (EIEC) as “Shigella/enteroinvasive E coli (EIEC).” V cholerae, V parahaemolyticus, and V vulnificus are detected and are reported as “Vibrio (parahae-
molyticus, vulnificus and cholerae); however, V cholerae is also reported independently if it alone is detected. Norovirus genogroups I and II are detected, and astrovirus
genotypes I, II, IV, and V are detected.
b The VERIGENE EP test detects C jejuni, C coli, and C lari and reports them as Campylobacter group. Shigella boydii, S dysenteriae, S flexneri, and S sonnei are detected
and reported as Shigella spp. V cholerae and V parahaemolyticus are detected and reported as Vibrio group. Norovirus genogroups I and II are detected.
c The xTAG GPP detectsC jejuni, C coli, and C lari and reports them asCampylobacter;Cryptosporidium parvum and C hominis, and reports them asCryptosporidium; and
S boydii, S dysenteriae, S flexneri, and S sonnei, and reports them as Shigella.
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TABLE 5
Multiplex Nucleic Acid Amplification Panels Available for the Detection of High-Consequence and Travel-Associated Pathogens
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FIG. 3 The FilmArray system. The FilmArray pouch (A) and (B) the FilmArray 2.0 and (C) Torch instruments.
(Courtesy of BioFire Diagnostics, Salt Lake City, UT; with permission.)
Syndromic and Point-of-Care Molecular Testing 107false positivity with norovirus using BioFire. Overall,
these platforms allow timely, accurate diagnosis of diar-
rhea and can assist with pathogen-directed therapy [42].
Respiratory
Owing to a relative paucity of accurate and rapid diagnos-
tics, pathogen determination in acute respiratory illness
had traditionally fallen to clinical presentation, despite
its poor prognostic value. Rapid, accurate diagnosis is crit-
ical for antibiotic stewardship, informing the clinician if
antivirals are warranted, and infection control initiatives
(eg, isolation, cohorting). Unsurprisingly, respiratory
illness has been a key target for syndromic testing (see Ta-
ble 2). Performance characteristics have been reviewed in
depth elsewhere [39], with key attributes highlighted
herein. All commercially available respiratory panels
significantly outperform traditionalmethods of detectionFIG. 4 The Curetis Unyvero system, composed of the U
(A, middle), and the Unyvero A50 Analyzer (A, right), and
Diego, CA; with permission.)and have expanded our recognition of coinfections
(approximately 5% of samples tested). At present, no
gold standard method for comparison of these assays
has hampered exact determination of performance; how-
ever, the generally accepted overall agreement between
molecular methods is between 85% and 99% for each
target, with some exceptions. Accurate detection of
adenovirus is problematic in many first-generation as-
says; however, a multicenter analysis of the FilmArray
RP2 [43] indicates increased sensitivity with this assay.
Sexually transmitted infections/women’s health
Sexually transmitted infections, bacterial vaginosis, and
vaginal yeast infections are associated with significant
morbidity and can have long-term consequences,
including infertility. The diagnosis of these highly prev-
alent infectious diseases once required the use ofnyvero L4 Lysator (A, left), the Unyvero C8 Cockpit
the Unyvero LRT panel (B). (Courtesy of Curetis, San
TABLE 6
Curetis Unyvero Lower Respiratory Tract Panel
for the Diagnosis of Community-Acquired and
Health Care-Associated Pneumonia
Microbial Targets
Antimicrobial Resistance
Genes
Acinetobacter spp.
Chlamydophila pneumoniae
Citrobacter freundii
Enterobacter cloacae
complex
Escherichia coli
Haemophilus influenzae
Klebsiella oxytoca
Klebsiella pneumoniae
Klebsiella variicola
Legionella pneumophila
Moraxella catarrhalis
Morganella morganii
Mycoplasma pneumoniae
Proteus spp.
Pseudomonas aeruginosa
Serratia marcescens
Staphylococcus aureus
Stenotrophomonas
maltophilia
Streptococcus
pneumoniae
blaTEM
blaSHV
blaVIM
blaNDM
blaKPC
blaCTX-M
blaOXA-23
blaOXA-24
blaOXA-48
blaOXA-58
gyrA83 mutation (of
Escherichia coli)
gyrA87 mutation (of E coli)
gyrA83 mutation (of
Pseudomonas
aeruginosa)
gyrA87 mutation (of
P aeruginosa)
mecA
FIG. 5 The Luminex VERIGENE system, composed of
Processor SP (A, right), and (B) a VERIGENE Test Cartr
permission.)
108 Relich & Abbottmultiple testing methods such as microscopy, culture,
and nucleic acid amplification testing; however, the
advent of syndromic testing systems for these patho-
gens (eg, BD MAX CT/GC/TV and BD MAX Vaginal
Panel; see Table 1) has streamlined their detection.
Overall, both of the assays listed in Table 1 outperform
traditional methods, including Chlamydia trachomatis
culture and microscopic screening for bacterial vagino-
sis, candidiasis, and trichomoniasis. In one study that
evaluated the performance of the BD MAX CT/GC/TV
assay, the sensitivities for detection of all three analytes
were 91.5% or greater and the specificities were 98.6%
or greater [14]. According to clinical trial data of the
BD MAX Vaginal Panel, the sensitivities for analytes
ranged from 75.9% (analyte [collection method]:
Candida glabrata [clinician-collected specimens]) to
100% (C glabrata [simulated specimens] and Candida
krusei [simulated specimens]) and specificities ranged
from 84.5% (bacterial vaginosis [self-collected speci-
mens]) to 100% (C glabrata [simulated specimens]
and C krusei [self-collected and simulated specimens])
[44]. Overall, sexually transmitted infection/women’s
health syndromic panels outperform traditional
methods in terms of sensitivity, specificity, and TATs.Currently Available Point-of-Care Molecular
Methods
The push to get faster diagnostic answers to guide
admission or discharge strategies and therapeutics is
likely to propel multiplex testing into the realm of(A, left) the VERIGENE Reader, (A, right) VERIGENE
idge. (Courtesy of Luminex, Austin, TX; with
FIG. 6 The Luminex MAGPIX instrument and computer for NxTAG and xTAG assays. (Courtesy of Luminex,
Austin, TX; with permission.)
Syndromic and Point-of-Care Molecular Testing 109POC testing. At present, issues with contamination,
quality control performance and monitoring, interpre-
tation of results, and overall good laboratory practices
as technologies migrate into a less controlled setting is
an obvious concern. Current CLIA-waived platforms
are discussed briefly, because these systems may be
readily adaptable to multiplex syndromic testing in
the POC setting.FIG. 7 The Alere i system, including the 3-part test cartr
of Alere, Waltham, MA; with permission.)Alere i
The Alere i (Alere Scarborough, Inc., Scarborough, ME;
Fig. 7) system uses nicking enzyme amplification reac-
tion technology, an isothermal amplification method,
to detect nucleic acids of target pathogens, including
influenza A and B viruses, respiratory syncytial virus,
and group A Streptococcus, either directly from swabs
or from swab eluates in transport media. The consum-
able is a 3-component system that consists of a reagentidge (left) and the Alere i instrument (right). (Courtesy
FIG. 9 The Quidel Solana instrument. (Courtesy of Quidel,
San Diego, CA; with permission.)
110 Relich & Abbottbase, elution buffer container, and transfer cartridge
that is assembled on the Alere i instrument. Positive re-
sults are available within 8 to 15 minutes (depending
on the assay type). Performance characteristics and
additional details are described in refs. [45–50].
cobas Liat system
The cobas Liat System (Roche Diagnostics, Indianapo-
lis, IN; Fig. 8) integrates all reagents necessary for
nucleic acid purification and amplification (by real-
time PCR) into a segmented soft plastic tube housed
within a rigid plastic frame. After specimen collection
(eg, nasopharyngeal swab) and elution into a suitable
specimen transport medium (eg, viral transport me-
dium), a small aliquot of the specimen is pipetted
into the tube, the tube is capped, and the entire tube-
frame assembly is loaded into the cobas Liat instru-
ment, which automates all reaction and amplicon
detection steps. Results for influenza detection are avail-
able within 20 minutes, and those for group A Strepto-
coccus are available within 15 minutes of assay
initiation. Currently, three FDA-cleared, CLIA-waived
assays are available for the detection of influenza A/B vi-
ruses alone, influenza A/B viruses and respiratory syncy-
tial virus, and group A Streptococcus. Performance
characteristics are discussed in refs. [45,51–53].
Solana
The Solana system (Quidel Corporation, San Diego,
CA; Fig. 9) uses isothermal, helicase-dependent amplifi-
cation and fluorescent-probe detection of target nucleicFIG. 8 The cobas Liat system from Roche Diagnostics
includes the test cartridge (foreground) and the Liat
instrument (background). (Courtesy of Roche Diagnostics,
Indianapolis, IN; with permission.)acids. Currently, FDA-approved assays are available for
the detection of Clostridium difficile, groups A and B
streptococci, herpes simplex viruses, varicella-zoster vi-
rus, influenza viruses, respiratory syncytial virus, hu-
man metapneumovirus, and Trichomonas vaginalis.
To perform testing, a patient specimen (eg, nasal
swab in viral transport medium) in Process Buffer is
heated before transfer to a reaction tube. The reaction
tube contains all reagents needed for amplification
and detection in a lyophilized form. The reaction tube
is next inserted into the Solana instrument where ampli-
fication and detection are performed. Results are avail-
able in 30 minutes or less. Up to 12 Solana diagnostic
assays can be analyzed simultaneously. Relevant perfor-
mance characteristics are described in ref. [54] and in
assay package inserts available on the Quidel website
(https://www.quidel.com).The Future of Syndromic Testing and Point-
of-Care Molecular Diagnostics
Each of these systems, plus those that have not been
described herein, are constantly undergoing refinement
to ensure their continued relevance in themolecular diag-
nostics marketplace. Test systems are continuously chal-
lenged with new strains of pathogens and antimicrobial
resistance mechanisms to evaluate their inclusivity and/
or exclusivity, and panels are frequently updated to
include additional analytes. Also, new assays that enable
detection and quantitation of pathogens associated with
disease processes besides those mentioned previously are
in development. The goal of most manufacturers is to
offer infectious disease diagnostic testing solutions that
allow identification of the greatest breadth of pathogens
Syndromic and Point-of-Care Molecular Testing 111associated with a specific disease process or syndrome. To
that end, future applications of these technologies
include the enhancement of currently available systems,
the development of additional panels that are amenable
to the diagnosis other infectious processes, and the devel-
opment of tests that enable users to comprehensively
profile the antimicrobial susceptibility of pathogens.SUMMARY
The use of multiplex panels for pathogen detection pro-
vides several advantages over traditional laboratory
diagnostic approach. Providers tout multiplex assays
as a means to simplify the ordering process, decrease
the number of required specimens, detect pathogens
that may not be part of the initial diagnostic differential
owing to rarity of the agent or inaccessibility of an alter-
native in-house test method, and provide results in a
clinically actionable timeframe. The incorporation of
molecular multiplex panels is of financial and logistical
benefit to the laboratory. Specifically, one can decrease
the number of methods needed to detect the same di-
versity of infectious agents and decrease technologist
hands-on time, which results in a simplified workflow
for the purposes of training, competency, use, and often
cost. For the patient, these assays provide superior accu-
racy over traditional approaches and a greater breadth
of targeted pathogens, which may decrease the number
of medical visits, interventions, and durations of diag-
nosis. Certain multiplex assays provide benefits beyond
direct patient care, such as early recognition of drug-
resistant pathogens for swift implementation of infec-
tion control measures or improved detection of gastro-
intestinal pathogens that may impact outbreak
investigations. Finally, rapid pathogen detection and
the potential for improved, early intervention has
been shown to positively impact associated costs by aid-
ing in selective test use and reduced length of stay [39].
Taken together, the benefits of molecular syndromic
panels and POC tests vastly outweigh any disadvan-
tages, which is centered around cost to the health care
system, namely, to the hospital or patient. The claim
that this so-called shotgun approach adds unnecessary
cost to the patient is an oversimplification. Although
molecular multiplex assays are often more costly in
terms of reagents and patient billing compared with a
single culture- or serology-based assay, when multiple
diagnostic tests are ordered, the multiplex assay is often
less expensive than the full battery of traditional tests.
Anecdotally, physicians desire to provide the patient
with a definitive diagnosis and treatment plan, which
may inadvertently lead to the overuse of medicalresources such as injudicious antibiotic use and addi-
tional diagnostic tests (eg, imaging) to help establish
a diagnosis when the causative pathogen is not easily
identified. Therefore, the ability to rapidly and accu-
rately provide a cause for the patient’s illness may
improve both physician and patient satisfaction.
At present, FDA-cleared syndromic and POC molecu-
lar assays center around a few syndromes; however, this
menu is likely to expand in the coming years as labora-
tories rapidly adopt this approach to testing. When com-
bined with consultation (eg, antimicrobial stewardship
intervention), the implementation of these assays has
been shown to decrease the time to appropriate therapy,
improve patient survival, and decrease overall health
care-associated costs [9]. Care must be taken in the selec-
tion and appropriate use of multiplex panels. Specif-
ically, one must balance the potential for increased
laboratory reagent and equipment costs against the po-
tential for reduced labor costs and increased revenue.
To provide the highest quality of care while limiting un-
necessary expense, laboratories must develop algorithms
that assist providers in test ordering and use.REFERENCES
[1] Daly JA, Clifton NL, Seskin KC, et al. Use of rapid,
nonradioactive DNA probes in culture confirmation
tests to detect Streptococcus agalactiae, Haemophilus
influenza, and Enterococcus spp. from pediatric patients
with significant infections. J Clin Microbiol 1991;29:
80–2.
[2] Davis TE, Fuller DD. Direct identification of bacterial iso-
lates in blood cultures by using a DNA probe. J Clin Mi-
crobiol 1991;29:2193–6.
[3] Lumb R, Lanser JA, Lim IS. Rapid identification of myco-
bacteria by the Gen-Probe Accuprobe system. Pathology
1993;25:313–5.
[4] Padhye AA, Smith G, Standard PG, et al. Comparative
evaluation of chemilluminescent DNA probe assays
and exoantigen tests for rapid identification of Blastomy-
ces dermatitidis and Coccidioides immitis. J Clin Microbiol
1994;32:867–70.
[5] Sninsky JJ. The polymerase chain reaction (PCR): a valu-
able method for retroviral detection. Lymphology 1990;
23:92–7.
[6] Persing DH, Mathiesen D, Marshall WF, et al. Detection
of Babesia microti by polymerase chain reaction. J Clin
Microbiol 1992;30:2097–103.
[7] Karron RA, Froehlich JL, Bobo L, et al. Rapid detection of
parainfluenza virus type 3 RNA in respiratory specimens:
use of reverse-transcription-PCR-enzyme immunoassay.
J Clin Microbiol 1994;32:484–8.
[8] Orlando C, Pinzani P, Pazzagli M. Developments in
quantitative PCR. Clin Chem Lab Med 1998;36:255–69.
112 Relich & Abbott[9] Abbott AN, Fang FC. Clinical impact of multiplex syn-
dromic panels in the diagnosis of bloodstream, gastroin-
testinal, respiratory, and central nervous system
infections. Clin Microbiol Newsl 2017;39:133–42.
[10] Messacar K, Hurst AL, Child J, et al. Clinical impact and
provider acceptability of real-time antimicrobial steward-
ship decision support for rapid diagnostics in children
with positive blood culture results. J Pediatric Infect
Dis Soc 2016;6:267–74.
[11] Rappo U, Schuetz AN, Jenkins SG, et al. Impact of early
detection of respiratory viruses by multiplex PCR assay
on clinical outcomes in adult patients. J Clin Microbiol
2016;54:2096–103.
[12] Ward C, Stocker K, Begum J, et al. Performance evalua-
tion of the Verigene (Nanosphere) and FilmArray
(BioFire) molecular assays for identification of causa-
tive organisms in bacterial bloodstream infections. Eur
J Clin Microbiol Infect Dis 2015;34:487–96.
[13] Salimnia H, Fairfax MR, Lephart PR, et al. Evaluation of
the FilmArray blood culture identification panel: results
of a multicenter controlled trial. J Clin Microbiol 2016;
54:687–98.
[14] Van Der Pol B. Profile of the triplex assay for detection of
chlamydia, gonorrhea, and trichomonas using the BD
MAX system. Expert Rev Mol Diagn 2017;17:539–47.
[15] Madison-Antenucci S, Relich RF, Doyle L, et al. Multi-
center evaluation of the BD MAX enteric parasite real-
time PCR assay for detection of Giardia duodenalis, Cryp-
tosporidium hominis, Cryptosporidium parvum, and
Entamoeba histolytica. J Clin Microbiol 2016;54:2681–8.
[16] Knabl L, Grutsch I, Orth-Höller D. Comparison of the
BD MAX enteric pathogen panel with conventional diag-
nostic procedures in diarrheal stool samples. Eur J Clin
Microbiol Infect Dis 2016;35:131–6.
[17] Simner PJ, Oethinger M, Stellrecht KA, et al. Multisite
evaluation of the BD MAX extended enteric bacterial
panel for detection of Yersinia enterocolitica, enterotoxi-
genic Escherichia coli, Vibrio, and Plesiomonas shigelloides
from stool specimens. J Clin Microbiol 2017;55:
3258–66.
[18] Nijhuis RHT, Guerendiain D, Claas ECJ. Comparison of
the ePlex respiratory pathogen panel with laboratory-
developed real-time PCR assays for detection of respira-
tory pathogens. J Clin Microbiol 2017;55:1938–45.
[19] Pierce VM, Hodinka RL. Comparison of the GenMark di-
agnostics eSensor respiratory viral panel to real-time PCR
for detection of respiratory viruses in children. J Clin Mi-
crobiol 2012;50:3458–65.
[20] Babady NE, England MR, Jurcic Smith KL, et al. Multi-
center evaluation of the ePlex respiratory pathogen panel
for the detection of viral and bacterial respiratory tract
pathogens in nasopharyngeal swabs. J Clin Microbiol
2018;56 [pii:e01658-17].
[21] Van Rijn AL, Nijhuis RHT, Bekker V, et al. Clinical impli-
cations of rapid ePlex respiratory pathogen panel testing
compared to laboratory-developed real-time PCR. Eur J
Clin Microbiol Infect Dis 2018;37:571–7.[22] McCoy MH, Relich RF, Davis TE, et al. Performance of the
FilmArray blood culture identification panel utilized by
non-expert staff compared to conventional microbial iden-
tification and antimicrobial resistance gene detection from
positive blood cultures. J Med Microbiol 2016;65:619–25.
[23] Rogers BB, Shankar P, Jerris RC, et al. Impact of a rapid
respiratory panel test on patient outcomes. Arch Pathol
Lab Med 2015;139:636–41.
[24] Kanack KJ. Rapid respiratory panel testing influences pa-
tient management and clinical outcomes. MLO Med Lab
Obs 2014;46:16.
[25] MacVane SH, Nolte FS. Benefits of adding a rapid PCR-
based blood culture identification panel to an estab-
lished antimicrobial stewardship program. J Clin Micro-
biol 2016;54:2455–63.
[26] Southern TR, Van Schooneveld TC, Bannister DL, et al.
Implementation and performance of the BioFire FilmAr-
ray blood culture identification panel with antimicrobial
treatment recommendations for bloodstream infections
at a midwestern academic tertiary hospital. Diagn Micro-
biol Infect Dis 2015;81:96–101.
[27] Buss SN, Leber A, Chapin K, et al. Multicenter evaluation
of the BioFire FilmArray gastrointestinal panel for etio-
logic diagnosis of infectious gastroenteritis. J Clin Micro-
biol 2015;53:915–25.
[28] Prakash VP, LeBlanc L, Alexander-Scott NE, et al. Use of a
culture-independent gastrointestinal multiplex PCR
panel during a shigellosis outbreak: considerations for
clinical laboratories and public health. J Clin Microbiol
2015;53:1048–9.
[29] Hanson KE, Slechta ES, Killpack JA, et al. Preclinical
assessment of a fully automated multiplex PCR panel
for detection of central nervous system pathogens.
J Clin Microbiol 2016;54:785–7.
[30] Duff S, Hasbun R, Ginocchio CC, et al. Economic anal-
ysis of rapid multiplex polymerase chain reaction testing
for meningitis/encephalitis in pediatric patients. Future
Microbiol 2018;13:617–29.
[31] Gay-Andrieu F, Magassouba N, Picto V, et al. Clinical
evaluation of the BioFire FilmArray BioThreat-E test for
the diagnosis of Ebola virus disease in Guinea. J Clin Vi-
rol 2017;92:20–4.
[32] Papan C, Meyer-Buehn M, Laniado G, et al. Assessment
of the multiplex PCR-based assay Unyvero pneumonia
application for detection of bacterial pathogens and anti-
biotic resistance genes in children and neonates. Infec-
tion 2018;46:189–96.
[33] Personne Y, Ozongwu C, Platt G, et al. ‘Sample-in,
answer-out’? Evaluation and comprehensive analysis of
the Unyvero P50 pneumonia assay. Diagn Microbiol
Infect Dis 2016;86:5–10.
[34] Ledeboer NA, Lopansri BK, Dhiman N, et al. Identifica-
tion of Gram-negative bacteria and genetic resistance de-
terminants from positive blood culture broths by use of
the Verigene Gram-negative blood culture multiplex
microarray-based molecular assay. J Clin Microbiol
2015;53:2460–72.
Syndromic and Point-of-Care Molecular Testing 113[35] Buchan BW, Ginocchio CC, Manii R, et al. Multiplex
identification of Gram-positive bacteria and resistance
determinants directly from positive blood culture broths:
evaluation of an automated microarray-based nucleic
acid test. PLoS Med 2013;10:e1001478.
[36] Esposito S, Principi N. The role of the NxTAG respiratory
pathogen panel assay and other multiplex platforms in
clinical practice. Expert Rev Mol Diagn 2017;17:9–17.
[37] Tang YW, Gonsalves S, Sun JY, et al. Clinical evaluation
of the Luminex NxTAG respiratory pathogen panel.
J Clin Microbiol 2016;54:1912–4.
[38] Huang RS, Johnson CL, Pritchard L, et al. Performance of
the Verigene enteric pathogens test, BioFire FilmArray
gastrointestinal panel and Luminex xTAG gastrointes-
tinal pathogen panel for detection of common enteric
pathogens. Diagn Microbiol Infect Dis 2016;86:336–9.
[39] Ramanan P, Bryson AL, Binnicker MJ, et al. Syndromic
panel-based testing in clinical microbiology. Clin Micro-
biol Rev 2017;31 [pii:e00024-17].
[40] Leber AL, Everhart K, Balada-Llasat JM, et al. Multicenter
evaluation of BioFire FilmArray Meningitis/Encephalitis
Panel for detection of bacteria, viruses, and yeast in cere-
brospinal fluid specimens. J Clin Microbiol 2016;54(9):
2251–61.
[41] Dien Bard J, Alby K. Point-counterpoint: meningitis/en-
cephalitis syndromic testing in the clinical laboratory.
J Clin Microbiol 2018;56(4) [pii:e00018-18].
[42] Cybulski RJ Jr, Bateman AC, Bourassa L, et al. Clinical
impact of a multiplex gastrointestinal PCR panel in pa-
tients with acute gastroenteritis. Clin Infect Dis 2018.
https://doi.org/10.1093/cid/ciy357.
[43] Leber AL, Everhart K, Daly JA, et al. Multicenter evaluation
of BioFire FilmArray Respiratory Panel 2 for detection of
viruses and bacteria in nasopharyngeal swab samples.
J Clin Microbiol 2018;25(6):56 [pii:e01945-17].
[44] Kawa D, Paradis S, Yu JH, et al. Evaluating the standard
of care for women’s health: the BD MAX Vaginal Panel
and management of vaginal infections (white paper).
2017. Available at: http://moleculardiagnostics.bd.com/
wp-content/uploads/2017/08/MAX-Vaginal-Panel-White
paper.pdf. Accessed June 25, 2018.
[45] Young S, Illescas P, Nicasio J, et al. Diagnostic accuracy of
the real-time PCR cobas Liat influenza A/B assay and theAlere i influenza A&B NEAR isothermal nucleic acid
amplification assay for the detection of influenza using
adult nasopharyngeal specimens. J Clin Virol 2017;94:
86–90.
[46] Davis S, Allen AJ, O’Leary R, et al. Diagnostic accuracy
and cost analysis of the Alere i influenza A&B near-
patient test using throat swabs. J Hosp Infect 2017;97:
301–9.
[47] Hassan F, Hays LM, Bonner A, et al. Multicenter clinical
evaluation of the Alere i respiratory syncytial virus
isothermal nucleic acid amplification assay. J Clin Micro-
biol 2018;56 [pii:e01777-17].
[48] Schnee SV, Pfeil J, Ihling CM, et al. Performance of the
Alere i RSV assay for point-of-care detection of respira-
tory syncytial virus in children. BMC Infect Dis 2017;
17:767.
[49] Cohen DM, Russo ME, Jaggi P, et al. Multicenter clinical
evaluation of the novel Alere i Strep A isothermal nucleic
acid amplification test. J Clin Microbiol 2015;53:
2258–61.
[50] Berry GJ, Miller CR, Prats MM, et al. Comparison of the
Alere i Strep A test and the BD Veritor system in the
detection of group A Streptococcus and the hypothetical
impact of results on antibiotic utilization. J Clin Micro-
biol 2018;56 [pii:e01310-17].
[51] Melchers WJG, Kuijpers J, Sickler JJ, et al. Lab-in-a-tube:
real-time molecular point-of-care diagnostics for influ-
enza A and B using the cobas Liat system. J Med Virol
2017;89:1382–6.
[52] Gibson J, Schechter-Perkins EM, Mitchell P, et al. Multi-
center evaluation of the cobas Liat Influenza A/B & RSV
assay for rapid point of care diagnosis. J Clin Virol
2017;95:5–9.
[53] Ling L, Kaplan SE, Lopez JC, et al. Parallel validation
of three molecular devices for simultaneous detection
and identification of influenza A and B and respira-
tory syncytial viruses. J Clin Microbiol 2018;56 [pii:
e01691-17].
[54] Gaydos CA, Schwebke J, Dombrowski J, et al. Clinical
performance of the Solana point-of-care trichomonas
assay from clinician-collected vaginal swabs and urine
specimens from symptomatic and asymptomatic
women. Expert Rev Mol Diagn 2017;17:303–6.
  
Since January 2020 Elsevier has created a COVID-19 resource centre with 
free information in English and Mandarin on the novel coronavirus COVID-
19. The COVID-19 resource centre is hosted on Elsevier Connect, the 
company's public news and information website. 
 
Elsevier hereby grants permission to make all its COVID-19-related 
research that is available on the COVID-19 resource centre - including this 
research content - immediately available in PubMed Central and other 
publicly funded repositories, such as the WHO COVID database with rights 
for unrestricted research re-use and analyses in any form or by any means 
with acknowledgement of the original source. These permissions are 
granted for free by Elsevier for as long as the COVID-19 resource centre 
remains active. 
 
